Short answer
NOVAVAX INC (NVAX) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results for quarter ended June 30, 2026.
NOVAVAX INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results for quarter ended June 30, 2026
- Press release issued August 6, 2026; detailed results in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $57M, down 76% year over year, reflecting the absence of prior-year $202M milestone and Takeda amendment benefits
- Net loss $53M versus $107M net income, while cash, securities and restricted cash totaled $724M at June 30
- Full-year adjusted revenue framework raised to $235M-$275M from $230M-$270M
- Combined R&D and SG&A expense guidance reduced by $10M midpoint to $370M-$410M
- Sanofi milestones offer upside: $125M for CIC trial initiation and $75M upon expected mid-2027 technology-transfer completion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NOVAVAX INC 8-K filings
Get the next NVAX 8-K as it lands
Follow NVAX for push alerts, or ask the research agent what this filing means.